Medicare on Tuesday announced the first 10 drugs selected for price negotiations, launching a historic and highly contentious process with big implications.
Merck, Johnson & Johnson and Amgen are among the first drugmakers to have products chosen for a contentious initiative to rein in prescription-drug costs.
The Novo Nordisk obesity drug semaglutide, marketed as Wegovy, can significantly reduce symptoms related to heart failure, according to a study published.